Late acute thrombosis after implantation of sirolimus‐eluting stent to treat in‐stent restenosis

Drug‐eluting stents (DES) have significantly reduced the incidence of in‐stent restenosis (ISR) compared to bare metal stents (BMS). However, recent randomized trials comparing DES with BMS reported few cases of late DES thrombosis. We report the case of late sirolimus‐eluting stent thrombosis occurring 22 months after its elective implantation in a restenotic BMS and soon after the interruption of combined anti‐platelet therapy with aspirin and Clopidogrel.     

Pancreatic reconstruction techniques after pancreaticoduodenectomy: a review of the literature

ABSTRACT

Introduction: Postoperative pancreatic fistula is the most troublesome complication after pancreaticoduodenectomy, and is an on-going area of concern for pancreatic surgeons. The specific pancreatic reconstruction technique is an important factor influencing the development of postoperative pancreatic fistula after pancreaticoduodenectomy.

Areas covered: In this paper, we briefly introduced the definition and relevant influencing factors of postoperative pancreatic fistula. We performed a search of all meta-analyses published in the last 5 years and all published randomized controlled trials comparing different pancreatic anastomotic techniques, and we evaluated the advantages and disadvantages of different techniques.

Expert opinion: No individual anastomotic method can completely avoid postoperative pancreatic fistula. Selecting specific techniques tailored to the patient’s situation intraoperatively may be key to reducing the incidence of postoperative pancreatic fistula.     

Optimizing endoscopic placement of expandable stents throughout the GI tract

Expandable stents have now become accepted for the relief of malignant obstruction throughout the GI tract and biliary system. Almost all expandable stents are composed of metal. More recently, an expandable plastic stent has been developed for the treatment of benign esophageal conditions. The clinical response to these devices is dependent on proper stent placement and anatomical location. Proper stent placement, in turn, is dependent on being familiar with the characteristics of the devices, having knowledge of the length of the stricture and anatomy, and the location of the obstruction within the GI tract. This review summarizes the available devices and techniques for optimal placement of expandable stents.     

New fully-covered self-expandable metal stent for endoscopic ultrasonography-guided intervention in infectious walled-off pancreatic necrosis (with video)

Endoscopic ultrasonography (EUS)-guided pancreatic pseudocyst drainage using a self-expandable metal stent (SEMS) has been reported for satisfactory drainage and endoscopic necrosectomy. Here, we described an interesting case in which successful endoscopic therapy was performed using a new SEMS in infectious walled-off pancreatic necrosis.     

Hemostasis using a fully covered self-expandable metal stent for marked bleeding from the bile duct following stent removal (with videos)

We describe a case of life-threatening hemorrhage from the bile duct following stent removal. Eventually, hemostasis was achieved by tamponade using a fully covered self-expandable metal stent.     

Metallic stents are more efficacious than plastic stents in unresectable malignant hilar biliary strictures: a randomized controlled trial

Background

Endoscopic biliary stenting is a well-established palliative treatment for unresectable malignant biliary strictures, for which plastic tube stents (PSs) and self-expandable metallic stents (SEMSs) are most commonly used. The efficacy of these stents has been extensively described in distal biliary strictures, but not in hilar biliary strictures. The present study aimed to compare the efficacy of PSs and SEMSs for unresectable malignant hilar biliary strictures.

Methods

From June 2004 to November 2008, 60 patients were enrolled and prospectively randomized into the PS or SEMS group.

Results

The 6-month patency rate was significantly higher in the SEMS group than in the PS group (81 vs. 20%; p = 0.0012). Kaplan–Meier analysis showed significantly longer patency in the SEMS group than in the PS group (p = 0.0002); the 50% patency period was 359 days in the SEMS group and 112 days in the PS group. There was no significant difference in the overall survival period between the PS and SEMS groups (p = 0.2834). The mean number of reinterventions for stent failures was significantly lower in the SEMS group (0.63 times/patient) than in the PS group (1.80 times/patient) (p = 0.0008). The overall total cost for the treatment was significantly lower in the SEMS group than in the PS group (p = 0.0222).

Conclusions

SEMSs were associated with a longer patency than PSs in patients with unresectable hilar biliary stricture. SEMSs were also more advantageous in reducing the number of reintervention sessions and the overall treatment cost.     

DSA透视下隆突定位法金属支架治疗恶性气道狭窄

目的探讨DSA透视下隆突定位法金属支架治疗恶性气道狭窄的疗效与安全性。方法对5例恶性气道狭窄患者在DSA透视下,采用隆突定位法行自膨胀金属支架置入术。结果 5例患者均一次性放置成功。患者的呼吸困难立即好转,呼吸困难指数由IV级将至0～I级。结论对于重度的恶性气道狭窄患者,根据胸部CT预先确定气管狭窄段与隆突间距离,DSA透视下隆突定位法金属支架置入术微创、安全、有效。     

Comparison of sirolimus-, paclitaxel-, and everolimus-eluting stent in unprotected left main coronary artery percutaneous coronary intervention

ObjectivesThis retrospective study evaluated the outcomes of patients who underwent unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with different types of drug-eluting stents (DES).BackgroundThe standard of care for patients with ULMCA is coronary artery bypass surgery. However, current guidelines recommend PCI in clinical conditions where there is an increased risk of adverse surgical outcomes. Clinical outcomes of patients undergoing ULMCA PCI with different types of drug-eluting stents (DES) are unknown.MethodsData from a multicenter international registry, which included 239 consecutive patients from four institutions who ULMCA PCI with DES, were collected.ResultsThere were 42 patients receiving paclitaxel-eluting stent (PES), 158 patients receiving sirolimus-eluting stent (SES), and 39 patients receiving everolimus-eluting stent (EES). There was no statistical difference in major adverse cardiovascular events, cardiac death, myocardial infarction, target lesion revascularization, and stent thrombosis among PES, SES, and EES at 30 days and 1 year.ConclusionsThere are no differences in clinical events among patients receiving PES, SES, and EES for ULMCA disease.     

H-FABP对冠脉支架术后近期心血管事件的预测

目的观察心肌脂肪酸结合蛋白对冠状动脉支架术后近期心血管事件的预测价值。方法入组90例成功择期PCI的冠心病患者,测定其冠脉支架术后3～6h内的H-FABP,并术后随访6个月,以发生心脏事件(包括心源性猝死,血管内再狭窄,充血性心力衰竭)为研究终点。结果经过6个月的随访,共有26例发生了心血管事件,其中心源性猝死1例,血管内再狭窄10例,充血性心力衰竭15例。心脏事件组H-FABP阳性率较无心血管事件组增高(P<0.05);Cox模型多因素逐步分析显示H-FABP阳性是冠脉支架术后再发心脏事件的独立危险因子(RR=5.82,P<0.05;95%CI 1.37～24.73)。结论 H-FABP阳性增加CHD患者支架术后6个月内发生心脏事件的风险,H-FABP阳性是冠心病冠脉支架术后心脏事件的独立危险因子。